缬沙坦治疗高血压伴心力衰竭的疗效及其对血清hs-CRP水平的影响

目的 探讨缬沙坦治疗高血压伴心力衰竭的疗效及其对血清超敏C反应蛋白(hs-CRP)水平的影响.方法 选择深圳市福永人民医院心内科于2015年12月至2016年12月期间收治的46例高血压伴心力衰竭患者为研究对象,根据随机数表法将患者分为观察组与对照组,每组23例,两组患者均予常规抗心衰治疗,对照组再应用苯磺酸氨氯地平降压,观察组则应用缬沙坦降压,疗程均为3个月.比较两组患者治疗前后的血压、左心室射血分数(LVEF)以及血清hs-CRP和脑钠肽(BNP)水平.结果 治疗后,观察组患者的收缩压(SBP)、舒张压(DBP)分别为(131.4±6.8)mmHg、(82.4±4.2)mmHg,与对照组的(134.9±6.7)mmHg、(83.9±3.8)mmHg比较,差异均无统计学意义(P>0.05);治疗后,观察组患者的血清hs-CRP、BNP水平分别为(7.3±2.2)mg/L、(131.5±43.2)pg/mL,明显低于对照组的(9.9±2.3)mg/L、(185.2±46.1)pg/mL,LVEF为(49.8±4.5)%,明显高于对照组的(46.3±3.3)%,差异均有统计学意义(P<0.05).结论 缬沙坦治疗高血压伴心衰不仅可以降低血压,且能够有效抑制炎症反应,进一步改善心功能.

Effect of valsartan on hypertension with heart failure and its influence on serum hypersensitive C-reactive protein level

Objective To investigate the effect of valsartan on hypertensive patients with heart failure and its effect on the hypersensitive C-reactive protein (hs-CRP). Methods Forty-six patients with hypertension heart failure who treated in Department of Cardiology in our hospital from December 2015 to December 2016 were selected as the re-search objects. According to the random number table, the patients were divided into observation group and control group, with 23 cases in each group. Two groups were treated with conventional anti heart failure. The control group was given amlodipines antihypertensive treatment, and the observation group was treated with valsartan for 3 months. The levels of blood pressure, left ventricular ejection fraction (LVEF), serum hs-CRP and brain natriuretic peptide (BNP) were compared between the two groups before and after treatment. Results After treatment, the systolic blood pressure (SBP) and diastolic blood pressure (DBP) were respectively (131.4±6.8) mmHg, (82.4±4.2) mmHg in observa-tion group, and (134.9±6.7) mmHg, (83.9±3.8) mmHg in the control group, with no significant differences between the two groups (P>0.05). After the treatment, the levels of serum hs-CRP, BNP in observation group were (7.3±2.2) mg/L, (131.5 ± 43.2) pg/mL, which were significantly lower than (9.9 ± 2.3) mg/L, (185.2 ± 46.1) pg/mL in control group. The LVEF in observation group was (49.8 ± 4.5)%, which was significantly higher than (46.3 ± 3.3)%in control group, P<0.05. Conclusion Valsartan in the treatment of hypertension and heart failure can not only reduce the blood pressure, but also can effectively inhibit the inflammatory reaction and improve heart function.